Patents by Inventor Ted Ebendal

Ted Ebendal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synergistic effects of OP/BMP morphogens and GDNF/NGF neurotrophic factors
    Patent number: 7507709
    Abstract: OP/BMP morphogen may be combined with GDNF/NGF neurotrophic factors to promote the survival or growth, or inhibit the death or degeneration, of mammalian cells, particularly neural cells, which express OP/BMP-activated serine/threonine kinase receptors and GDNF/NGF-activated tyrosine kinase receptors. Also disclosed are methods for the treatment of such cells, including treatments for mammals afflicted with, or at imminent risk of, damage or injury to, such cells, as well as new pharmaceutical preparations for such treatments.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: March 24, 2009
    Assignee: Stryker Corporation
    Inventors: Marc F. Charette, Ted Ebendal, David C. Rueger
  • Synergistic effects of OP/BMP morphogens and GDNF/NGF neurotrophic factors
    Patent number: 6936582
    Abstract: OP/BMP morphogen is combined with GDNF/NGF neurotrophic factors in promoting the survival or growth, or inhibiting the death or degeneration, of mammalian cells, particularly neural cells, which express OP/BMP-activated serine/threonine kinase receptors and GDNF/NGF-activated tyrosine kinase receptors. Also discosed are methods for the treatment of such cells, including treatments for mammals afflicted with, or at imminent risk of, damage or injury to, such cells, as well as new pharmaceutical preparations for such treatments.
    Type: Grant
    Filed: September 9, 1998
    Date of Patent: August 30, 2005
    Assignee: Curis, Inc.
    Inventors: Marc F. Charette, Ted Ebendal, David C. Rueger
  • Synergistic effects of OP/BMP morphogens and GDNF/NGF neurotrophic factors
    Publication number: 20050164938
    Abstract: OP/BMP morphogen may be combined with GDNF/NGF neurotrophic factors to promote the survival or growth, or inhibit the death or degeneration, of mammalian cells, particularly neural cells, which express OP/BMP-activated serine/threonine kinase receptors and GDNF/NGF-activated tyrosine kinase receptors. Also disclosed are methods for the treatment of such cells, including treatments for mammals afflicted with, or at imminent risk of, damage or injury to, such cells, as well as new pharmaceutical preparations for such treatments.
    Type: Application
    Filed: March 18, 2005
    Publication date: July 28, 2005
    Inventors: Marc Charette, Ted Ebendal, David Rueger
  • Methods for treating neurological injuries and disorders
    Patent number: 6872698
    Abstract: The present invention relates to methods for treatment of nerve cell death (degeneration) and neurodegenerative diseases. Methods of the invention include administering, an effective amount of GDF-1 alone or in combination with neurotrophin-3, to a patient in need of such treatment such as a person suffering from stroke or traumatic brain injury or a neurodegenerative disease.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: March 29, 2005
    Assignee: Scion Pharmaceuticals, Inc.
    Inventors: Mark Marchionni, Michael Jarpe, Ted Ebendal
  • Methods for treating neurological injuries and disorders
    Publication number: 20030069176
    Abstract: The present invention relates to methods for treatment of nerve cell death (degeneration) and neurodegenerative diseases. Methods of the invention include administering, an effective amount of GDF-1 alone or in combination with neurotrophin-3, to a patient in need of such treatment such as a person suffering from stroke or traumatic brain injury or a neurodegenerative disease.
    Type: Application
    Filed: January 8, 2001
    Publication date: April 10, 2003
    Applicant: Cambridge NeuroScience, Inc.
    Inventors: Mark Marchionni, Michael Jarpe, Ted Ebendal